Abstract
Background aims
Before autologous stem cell transplantation (ASCT), hematopoietic stem cells must
be stimulated to move from the bone marrow to the peripheral blood for harvesting.
Plerixafor, a C-X-C chemokine receptor type 4 antagonist, is used to increase stem
cell harvests. However, the effects of plerixafor on post-ASCT outcomes remain unclear.
Methods
In a dual-center retrospective cohort study of 43 Japanese patients who received ASCT,
the authors compared transplantation outcomes in patients who underwent stem cell
mobilization with granulocyte colony-stimulating factor with (n = 25) or without (n = 18)
plerixafor.
Results
The number of days to neutrophil and platelet engraftment was significantly shorter
with plerixafor than without plerixafor, as assessed by univariate (neutrophil, P = 0.004, platelet, P = 0.002), subgroup, propensity score matching and inverse probability weighting analyses.
Although the cumulative incidence of fever was comparable with or without plerixafor
(P = 0.31), that of sepsis was significantly lower with plerixafor than without (P < 0.01). Thus, the present data indicate that plerixafor leads to earlier neutrophil
and platelet engraftment and a reduction of infectious risk.
Conclusions
The authors conclude that plerixafor may be safe to use and that it reduces the risk
of infection in patients with a low CD34+ cell count the day before apheresis.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Blood. 2011; 117: 6063-6073
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.Leukemia. 2014; 28: 1122-1128
- Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review.Ann Oncol. 1993; 4: 7-13
- Autologous stem cell transplantation beyond 60 years of age.Bone Marrow Transplant. 2006; 38: 715-720
- Advances in mobilization for the optimization of autologous stem cell transplantation.Leuk Lymphoma. 2009; 50: 1412-1421
- Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.Biol Blood Marrow Transplant. 2014; 20: 295-308
- Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.Blood. 1992; 80: 1666-1672
- Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting.Bone Marrow Transplant. 1992; 10: 215-220
- Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era.Clin Lymphoma Myeloma Leuk. 2019; 19: 200-205
- Autologous Stem Cell Mobilization and Collection.Hematol Oncol Clin North Am. 2016; 30: 573-589
- CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent.Pharmacol Res. 2020; 159105010
- Plerixafor for stem cell mobilization: the current status.Curr Opin Hematol. 2016; 23: 67-71
- Plerixafor: a peripheral blood stem cell mobilizer.Pharmacotherapy. 2010; 30: 485-492
- A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.Clin Ther. 2010; 32: 821-843
- Effectiveness of an alogorithm-based approach to the utilization of plerixafor in patients undergoing chemotherapy-based stem cell mobilization.Biol Blood Marrow Transplant. 2014; 20: 1064-1068
- Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients.Hematol Oncol. 2022; https://doi.org/10.1002/hon.3055
- Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease.Br J Haematol. 2022; 198: 740-744
- Predictors of poor haematopoietic stem cell mobilisation in patients with haematological malignancies at a South African centre.Transfus Apher Sci. 2022; 61: 103419
- Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: a single center comparison of GCSF+/– plerixafor vs cyclophosphamide/GCSF+/– plerixafor.J Clin Apher. 2022; 37: 348-353
- Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting.Biol Blood Marrow Transplant. 2011; 17: 943-955
N Tsukada, M Nishikori, H Goto, R Kanamori, S Nishina, et al. Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study. Drugs Real World Outcomes. 2022; 9(1): 63-78.
- Evaluation of CD34+ Cell Count at Different Time Points Following Plerixafor Administration in Autologous Hematopoietic Stem Cell Transplantation.Int J Cancer Manage. 2022; 15e120241
- The vision of Japanese guidelines for the proper use of G-CSF and future perspective.Ann Oncol. 2016; 27: 1257-1266
- Autologous haematopoietic stem cell mobilization in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Bone Marrow Transplant. 2014; 49: 865-872
- Revised response criteria for malignant lymphoma.J Clin Oncol. 2007; 25: 579-586
- Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.Br J Haematol. 2003; 121: 749-757
- Two-sided Exact Tests and Matching Confidence Intervals for Discrete Data.R Journal. 2010; 20: 53-58
- Effectiveness of supplemental oral calcium drink in preventing citrate-related adverse effects in peripheral blood progenitor cell collection.Transfus Apher Sci. 2021; 60103147
- Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.Stat Med. 1999; 18: 695-706
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics.Bone Marrow Transplant. 2013; 48: 452-458
- Nonparametric Estimation of a Recurrent Survival Function.J Am Stat Assoc. 1999; 94: 146-153
- Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.Cytotherapy. 2022; 24: 49-58
- Bone Marrow Transplant. 2014; 20: 1262-1273
- Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with plerixafor: a retrospective, multicenter study of a large series of patients.Transfus Apher Sci. 2021; 60103130
- Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.Transfusion. 2014; 54: 1243-1250
Yogo T, Tsukada N, Nashimoto J, Uto Y, Sato K, et al. Plerixafor-mobilized patients have a high risk of non-infectious fever during engraftment after autologous peripheral blood stem cell transplantation. 45th Annual Meeting of the European Society for Blood and Marrow Transplantation. 24–27 March 2019.
- Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria.Bone Marrow Transplant. 2003; 31: 393-397
- Plerixafor strategies for autologous hematopoietic cell transplant mobilization: a comparison of efficacy and cost.Transfus Apher Sci. 2022; 61103303
- Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.Biol Blood Marrow Transplant. 2018; 24: 1187-1195
- Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor.Bone Marrow Transplant. 2020; 55: 613-622
- Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study.Leuk Lymphoma. 2019; 60: 453-461
- Self-repopulating recipient bone marrow resident macrophages promote long-term hematopoietic stem cell engraftment.Blood. 2018; 132: 735-749
- Alcam regulates long-term hematopoietic stem cell engraftment and self-renewal.Stem Cells. 2013; 31: 560-571
- Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression.Cell Stem Cell. 2014; 14: 810-823
- Prolonged fasting/refeeding promotes hematopoietic stem cell regeneration and rejuvemation.Rejuvenation Res. 2014; 17: 385-389
- Patients with lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow.Bone Marrow Transplant. 2003; 31: 23-29
- PBSCT is associated with poorer survival and increased chronic GVHD than BMT in Japanese pediatric patients with acute leukemia and an HLA-matched sibling donor.Pediatr Blood Cancer. 2013; 60: 1513-1519
- Peripheral blood or bone marrow cells in reduced intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.Haematologica. 2017; 92: 1513-1518
- Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis.Ann Hematol. 2021; 100: 2339-2350
- Peripheral blood stem cells for allogeneic transplantation.Bone Marrow Transplant. 1996; 18: 171-174
- The intricate role of CXCR4 in cancer.Adv Cancer Res. 2014; 124: 31-82
- The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration.Front Immunol. 2020; 11: 2109
- CXCR4 and cancer.Pathol Int. 2010; 60: 497-505
- Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms; pivotal role of the SDF-1-CXCR4 axis.Stem Cells. 2005; 23: 879-894
- Pan-cancer analysis of CXCR4 carcinogenesis in human tumors.Transl Cancer Res. 2021; 10: 4180-4195
- Insights into the mechanism of enhanced mobilization of hematopoietic progenitor cells and release of CXCL12 by a combination of AMD3100 and aminoglycoside-polyarginine conjugates.FEBS J. 2011; 278: 4150-4165
- CXCR4 receptor blockage reduced the contribution of tumor and stromal cells to the metastatic growth in the liver.Oncol Rep. 2018; 39: 2022-2030
- CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.Haematologica. 2020; 105: 1361-1368
- Cell Cycle-Associated CXCR4 Expression in Germinal Center B Cells and Its Implications on Affinity Maturation.Front Immunol. 2018; 9: 1313
- Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells.Int J Nanomedicine. 2021; 16: 1869-1888
- CXCR4 promotes B cell viability by the cooperation of nuclear factor (erythroid-derived 2)-like 2 and hypoxia-inducible factor-1α under hypoxic conditions.Cell Death Dis. 2021; 12: 330
- Involvement of chemokine receptors in breast cancer metastasis.Nature. 2021; 410: 50-56
- CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis.Life Sci. 2020; 249117534
- A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells.Sci Signal. 2011; 4: ra60
- CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization.Curr Pharm Des. 2010; 16: 3903-3920
- CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival.J Pathol. 2015; 235: 445-455
Article info
Publication history
Published online: March 12, 2023
Accepted:
February 13,
2023
Received:
November 8,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
